Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Tirzepatide shows promise for menstrual health. A new analysis from the Apple Women's Health Study found that women using a dual GLP-1/GIP receptor agonist (tirzepatide) had notably shorter and more consistent menstrual cycles compared to GLP-1-only users and non-users. The effect was even more pronounced in women with polycystic ovary syndrome (PCOS), suggesting the drug may support ovulatory health beyond just metabolic benefits.
Tirzepatide may do more than help with weight loss — it could regulate periods too. A new prospective analysis presented at the American Society for Reproductive Medicine (ASRM) annual meeting found that women using a dual GLP-1/GIP receptor agonist (tirzepatide/Zepbound) experienced greater reductions in menstrual cycle length and variability compared to those on GLP-1-only drugs or no medication. Researchers drew on data from the Apple Women's Health Study, a longitudinal digital cohort of ~147,000 U.S. women tracking their menstrual cycles via iPhone.
The findings were especially striking in women with polycystic ovary syndrome (PCOS), where cycle variability dropped to 5.80 days for tirzepatide users vs. 9.45 days for non-users — suggesting the drug may target ovulatory health through pathways beyond metabolic improvement alone.
By the Numbers:
Why it matters: Over 10 million U.S. women use GLP-1 or GLP-1/GIP drugs, yet their effects on reproductive health have been understudied. This is one of the first prospective analyses to examine menstrual regularity as a primary endpoint, opening the door for these medications to be considered in women's reproductive care — particularly for PCOS patients.
